Prime Genomics

1
Prime Genomics

• Population Screening for Breast Cancer through
  Saliva

2
Mission

• Prime Genomics seeks to leverage its proprietary
  marker identification technology to commercialize
  its breast cancer population screening marker.
• This marker diagnoses breast cancer from saliva
  samples prior to mammography in markets and
  situations where mammography is unavailable or
  undesirable.

3
Problem

• Lack of early detection of breast cancer due to
  compliance and availability leads to increased
  cost of intervention and reduced survival rates.
• In developed countries, the mammogram compliance
  rate for women within recommended guidelines is
  only 50 due to the embarrassing, uncomfortable,
  and painful aspects of the procedure.
• In lesser-developed countries, access to
  mammograms is limited due to cost and the lack of
  availability of mammography equipment.

4
Solution

• Prime Genomics has identified a diagnostic
  signature indicative of breast cancer in saliva
  samples with comparable results to mammography.
• Saliva samples are easy to obtain and transport
  to central labs. Analysis is performed on FDA
  cleared equipment Affymetrix microarrays.

5
Technology

• Proprietary, IP protected, whole microarray tool
  evaluates expression patterns of 8,000 genes
  simultaneously.
• Expression pattern of all 8,000 genes returns a
  single number correlating to the presence,
  absence and relative strength of the signal.
• The signal can be used to indicate disease as
  well as therapeutic response. It can serve as a
  companion diagnostic tool for a wide range of
  molecular targets.

6
Technology

• Start with gene expression data
• Examine interactions between all genes
• Find the equilibrium state
• Quantify it with one informative number

7
Technology

• Finds biomarkers across the genome
• Finds biomarkers across disease states
• Severity/response is inherent
• Clinical diagnostics
• Patient stratification
• Biomarker interpretation is SIMPLE
• Single platform for all analysis

8
Technology
9
Market Opportunity

• Breast cancer diagnostics currently represents a
  6 billion global market.
• In the US, 200,000 women are diagnosed with
  breast cancer each year. The ACS recommends
  annual breast-cancer screening after age 40.
• The annual compliance rate in the US is about
  50. A saliva test, rather than a mammogram, can
  significantly increase that compliance rate via
  annual check-ups.
• There are approximately 20 million pre-menopausal
  women in the US where routine screening is
  advised.
• At expected revenues of 250 - 500 per test, the
  market opportunity in the US alone could be up to
  10B relative to the 2B market it is today.

10
Strategy

• Prime Genomics is seeking to validate its breast
  cancer saliva marker via a 200 patient study.
• PG is partnering with a molecular diagnostics
  company based in India to conduct the study.
• Partner believes that study will be sufficient to
  commercialize the test in Indian sub-continent.
• Partner will fund patient sample collection and
  analysis. PG will conduct algorithmic analysis.
• Partner will have exclusive rights to
  commercialize the test in India and related
  markets with royalty payments to PG.
• PG retains rights to data from trial.

11
Strategy

• Following marker validation in the Indian trial,
  we expect to find a partner to further develop
  and commercialize the marker in exchange for
  license fees, milestone payments and royalties.
• PG will then select another of its discovered
  markers to similarly validate and partner.
• The technology platform gains validation with
  each additional confirmed test, allowing PG to
  identify alternatives for monetizing the platform.

12
Team

• Sandy Shaw, PhD.(ABD), Founder/CEO,
  bioinformatics research at University of
  California, San Francisco. Fractal Genomics
  founder and President, Developed biomarkers
  related to AIDS and leukemia. Holder of US and
  Europeans patents in the fields of data analysis,
  gene expression modeling, and biomarker
  discovery.
• Scott Greenstone, CFA -Corporate Development
  Equity research at Salomon Bros Thomas Weisel
  Partners. Finance and strategy/corporate
  development at Xenogen, Symyx and Varian.
• Steve Smith, PhD., Scientific advisor - FivePrime
  Therapeutics, Caliper Life Sciences and Bayer
  post doctoral research fellow at The Gladstone
  Institute for Cardiovascular Disease.
• James Bennington, M.D., Scientific advisor -
  retired Chairman of the Anatomical Pathology
  Department and Clinical Laboratories of the
  California Pacific Medical Center in San
  Francisco

13
Investment

• Seeking 375,000 preferred equity at 2 million
  pre-money valuation.
• Use of proceeds to fund PGs obligations for
  Indian clinical trial (trial design and
  monitoring consultants) and other business and
  corporate development activities.
• Further funding requirements depend on trial
  results.